Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.65), FiscalAI reports. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $15.00 million.
Zenas BioPharma Price Performance
ZBIO stock opened at $29.56 on Friday. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04. Zenas BioPharma has a one year low of $13.50 and a one year high of $44.60. The firm has a market capitalization of $1.87 billion, a PE ratio of -3.46 and a beta of -1.03. The firm has a 50-day moving average of $26.71 and a two-hundred day moving average of $23.34.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Guggenheim reaffirmed a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a report on Friday. Zacks Research upgraded Zenas BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, May 15th. Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Finally, Wedbush restated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Zenas BioPharma currently has a consensus rating of “Moderate Buy” and an average price target of $44.29.
Insider Buying and Selling at Zenas BioPharma
In other news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were acquired at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the transaction, the chief executive officer directly owned 96,928 shares in the company, valued at approximately $1,636,144.64. The trade was a 162.48% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 22.00% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Zenas BioPharma
Several hedge funds have recently made changes to their positions in ZBIO. Geode Capital Management LLC grew its position in Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock worth $3,621,000 after purchasing an additional 16,461 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Zenas BioPharma by 71.3% in the second quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares in the last quarter. Sei Investments Co. acquired a new stake in shares of Zenas BioPharma in the second quarter worth $118,000. Bank of America Corp DE boosted its position in shares of Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company’s stock worth $136,000 after buying an additional 3,412 shares during the period. Finally, Vanguard Group Inc. grew its holdings in shares of Zenas BioPharma by 17.2% during the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after buying an additional 170,546 shares in the last quarter.
About Zenas BioPharma
Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.
Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.
Featured Stories
- Five stocks we like better than Zenas BioPharma
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
